Scholar Rock Q2 Loss Narrows Slightly; Cash Runway Extended Into 2027 Ahead of September PDUFA
SRRK sits 94% above its 52-week low of $27.07.
Summary
Scholar Rock reported a slightly narrower Q2 loss and extended its cash runway into 2027, positioning for the September 30 PDUFA decision on apitegromab. The company raised significant capital through ATM sales and a new debt facility, while ramping up commercial preparations.
Key Events · Earnings and Guidance · SRRK
-
Q2 Loss Narrows Slightly
Net loss of $109.9M vs $110.0M in Q2 2025; R&D expenses fell 6.7% to $58.2M, while G&A rose 1.9% to $50.7M.
-
Cash Runway Extended Into 2H 2027
Cash, equivalents, and marketable securities totaled $492.1M at June 30, 2026, up from $367.6M at year-end 2025, driven by $160.8M in ATM sales and $200M in debt draws.
-
PDUFA Date Set for September 30, 2026
FDA accepted the BLA resubmission for apitegromab in SMA with a September 30, 2026 action date; approval hinges on resolution of a third-party fill-finish facility's OAI classification.
-
Commercial Build-Out Accelerates
G&A expenses surged 29% YoY to $100.9M for H1 2026, reflecting hiring of commercial and field-facing teams ahead of a potential apitegromab launch.
Analysis · SRRK · Life Sciences
A marginal improvement in Scholar Rock's bottom line—net loss narrowed to $109.9 million from $110.0 million a year ago—was overshadowed by a much stronger balance sheet. Cash, equivalents, and marketable securities climbed to $492.1 million, extending the runway into the second half of 2027. The company fortified its position through $160.8 million in ATM share sales and a $200 million draw from a new Blue Owl debt facility, all ahead of the September 30, 2026 PDUFA date for apitegromab in SMA. Reflecting the urgency of a potential launch, general and administrative expenses jumped 29% to $100.9 million for the first half of 2026, driven by the build-out of a commercial infrastructure. The BLA resubmission was accepted after a prior CRL, and a Phase 2 trial in FSHD was initiated, broadening apitegromab's opportunity. The key risk remains the FDA's resolution of the third-party fill-finish facility's OAI classification, which could delay or derail approval.
At the time of this filing, SRRK was trading at $52.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $27.07 to $58.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.